However, they reported a significant elevation of sPD-L1 in non-responders at the moment of the first tumor evaluation under nivolumab, and higher ORR in patients with decreased or stable sPD-L1 concentrations from the start of immunotherapy to the first tumor evaluation [28]. The gene discussed is SPDL1; the disease is neoplasm.